Last Update 23 Jul 26
Fair value Decreased 12%IONS: Tryngolza Approval And Rare Disease Pipeline Will Reshape 2026 Risk Reward Profile
Ionis Pharmaceuticals' fair value estimate has been reset from $104.86 to $92.00, as analysts incorporate the Phase 3 eplontersen cardiomyopathy miss, related trims to revenue growth and profit margin assumptions, and a higher projected future P/E. These factors are all reflected in a wave of reduced price targets across the Street.
Analyst Commentary
Street research on Ionis Pharmaceuticals has shifted quickly after the eplontersen cardiomyopathy miss, with most firms recalibrating targets rather than abandoning the longer-term story. For you as an investor, the key debate is whether recent trial setbacks mainly cap near-term upside or fundamentally change the growth trajectory that underpins higher valuation multiples.
Bullish Takeaways
- Bullish analysts largely maintain positive ratings while trimming targets, arguing that Ionis Pharmaceuticals still has an "impressive" and diversified pipeline where only a few assets are fully reflected in current valuation.
- Several price target updates explicitly remove cardiomyopathy-related revenue for eplontersen or Wainua, yet retain Buy or Overweight views. This signals confidence that other commercial launches and partnered programs can support earnings and cash generation over time.
- Recent FDA approval of Tryngolza is seen as an important proof point, with some analysts highlighting its lead role within Ionis Pharmaceuticals' proprietary pipeline and pointing to large modeled opportunities in severe hypertriglyceridemia and pancreatitis risk reduction.
- Some research cites a strong revenue-generating base, existing partnerships, and a business already described as meaningfully profitable as reasons why downside risk is viewed as limited relative to potential upside from future execution.
Bearish Takeaways
- Bearish analysts flag that two separate trial disappointments in TTR and tau have removed large pieces of the earlier bull thesis and pushed remaining upside drivers further out in time, which can weigh on sentiment and delay any re-rating in the stock's P/E.
- Several firms remove eplontersen in ATTR-CM from their models entirely and see no clear regulatory path for cardiomyopathy, cutting price targets accordingly and underscoring how sensitive Ionis Pharmaceuticals' valuation is to late-stage clinical outcomes.
- Some commentary suggests that recent trial failures may benefit competitors in ATTR, with other TTR-directed therapies framed as better positioned commercially, which could limit Ionis Pharmaceuticals' ability to capture market share in certain indications.
- Downgrades to neutral stances highlight that while there may still be upside catalysts, investors face execution risk around future launches and trial readouts, and that the near-term risk or reward skew is less compelling after the recent data setbacks.
What’s in the News for Ionis Pharmaceuticals
- Biogen presented Phase 2 CELIA data for diranersen, partnered with Ionis Pharmaceuticals, in early Alzheimer’s disease, showing meaningful clinical efficacy across multiple endpoints and robust reductions in cerebrospinal fluid and brain tau pathology, with plans to move into confirmatory Phase 3 development (source: Ionis and Biogen at AAIC).
- AstraZeneca and Ionis reported that the CARDIO-TTRansform Phase 3 trial of eplontersen, or Wainua, in transthyretin-mediated amyloid cardiomyopathy did not meet its primary endpoint for reducing cardiovascular death and recurrent cardiovascular events versus placebo, which was followed by a sharp fall in both companies’ stocks and raised questions around the ATTR-CM opportunity (multiple sources).
- Ionis began dosing in the Phase 1/2 ASCEND study of ION337 for Dravet syndrome, using its next generation NMA technology in a potential disease modifying RNA therapy for children aged 2 to 12 years, with the trial focused on safety, tolerability and the potential for infrequent dosing (company announcement).
- Ionis completed enrollment in the pivotal pediatric cohort of the global Phase 3 REVEAL study for obudanersen in Angelman syndrome, with 136 participants aged 2 to under 18 years and plans for additional adult trials, positioning this program as a key late stage rare disease asset (company announcement).
- The U.S. FDA approved Tryngolza, olezarsen, from Ionis Pharmaceuticals as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia, based on Phase 3 CORE and CORE2 data showing up to 72% triglyceride reduction and up to 91% fewer acute pancreatitis events versus placebo, establishing a new treatment option in this high risk population (company announcement).
Valuation Changes for Ionis Pharmaceuticals
- Fair Value: Reset from $104.86 to $92.00, reflecting a reduction of around 12% in the central valuation mark for Ionis Pharmaceuticals.
- Discount Rate: Adjusted from 7.44% to 7.62%, a slight increase that implies a marginally higher required return on the stock.
- Revenue Growth: Trimmed from 31.02% to 27.01%, signaling more conservative assumptions for future revenue expansion in dollar terms.
- Net Profit Margin: Reduced from 13.86% to 9.78%, indicating lower expected long-term earnings capture per dollar of sales.
- Future P/E: Raised from 72.56x to 99.49x, pointing to a higher assumed valuation multiple on forward earnings within the updated model.
0 viewsusers have viewed this narrative update
Key Takeaways
- Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth.
- Strategic partnerships, growing royalties, and a competitive edge in rare disease commercialization enhance financial resilience and support margin expansion.
- Expanding into broader indications and dependence on key late-stage assets heighten pricing pressures, regulatory risks, and limit revenue and margin growth amid market and partner challenges.
Catalysts
About Ionis Pharmaceuticals- A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
- The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.
- Expanding addressable patient populations-from rare diseases to larger segments like severe hypertriglyceridemia (sHTG)-combined with favorable physician feedback and significant unmet need, position Ionis to capture substantial market share and revenue growth from trends tied to the rise in chronic disease and an aging population.
- Greater acceptance of RNA-targeted and antisense oligonucleotide (ASO) therapies among physicians, regulators, and payors, demonstrated by positive reimbursement outcomes, coverage expansions, and robust adoption, supports Ionis' potential to improve gross and net margins over time as its innovative therapies become increasingly mainstream.
- Ionis' growing stream of high-margin royalty and milestone revenues from partnerships (e.g. Biogen, AstraZeneca, Roche), as well as recent substantial out-licensing deals, provides both capital efficiency and financial resilience-helping shore up net margins and reducing risk as operating expenses scale with new launches.
- The company's proven ability to rapidly identify, educate, and enroll patients in rare diseases-leveraging omnichannel and specialty networks-signals a first-mover and competitive advantage in precision medicine, supporting revenue durability and premium pricing amid expanding payor willingness to reimburse high-value, personalized therapies.
Ionis Pharmaceuticals Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Ionis Pharmaceuticals's revenue will grow by 27.0% annually over the next 3 years.
- Analysts assume that profit margins will increase from -30.9% today to 9.8% in 3 years time.
- Analysts expect earnings to reach $212.1 million (and earnings per share of $0.99) by about July 2029, up from -$327.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $679.0 million in earnings, and the most bearish expecting $-549.3 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 99.6x on those 2029 earnings, up from -27.3x today. This future PE is greater than the current PE for the US Biotechs industry at 16.5x.
- Analysts expect the number of shares outstanding to grow by 3.68% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.62%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- Ionis faces a significant risk of revenue compression as it expands Olezarsen from a rare-disease (FCS) to a broader (sHTG) indication, with management openly discussing that a price reduction will be necessary to address the much larger patient populations-potentially leading to a step-down in average net price and limiting long-term margin growth and earnings expansion.
- The company's increasing reliance on a few late-stage assets and upcoming FDA approvals (notably for Donidalorsen and Olezarsen in sHTG) highlights high regulatory and execution risk: setbacks or delays in pivotal data (e.g., insufficient acute pancreatitis outcomes, ambiguity around meaningful endpoints, or label negotiations) could disrupt the launch cadence and result in "lumpy" or stagnating revenue and net income.
- Slowdown in new patient identification beyond "low hanging fruit" populations (e.g., initial trial participants or previously diagnosed rare disease patients) suggests that longer-term growth in rare indications like FCS may be constrained by diagnosis rates and market penetration challenges, dampening the sustainability of revenue momentum.
- Ionis admits it is not currently building out ex-U.S. infrastructure and will continue to rely on third-party partners (e.g., Sobi, AstraZeneca) for global commercialization, meaning any changes in strategy, performance, or prioritization by these partners could materially impact royalties, milestone revenues, and overall revenue diversification.
- Anticipated large-scale pricing negotiations for expanded indications and payer resistance, especially as Ionis targets larger, less severe patient populations, expose the company to global drug pricing pressures and reimbursement complexities, elevating the risk that gross-to-net realization and ultimate revenue growth may fall short of expectations as biosimilars, generics, or competitive modalities (such as CRISPR and new RNA therapies) emerge.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $92.0 for Ionis Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $125.0, and the most bearish reporting a price target of just $66.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $2.2 billion, earnings will come to $212.1 million, and it would be trading on a PE ratio of 99.6x, assuming you use a discount rate of 7.6%.
- Given the current share price of $54.01, the analyst price target of $92.0 is 41.3% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Ionis Pharmaceuticals?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Read more narratives
US$79.71
FV
29.9% undervalued intrinsic discount67
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$130
FV
57.0% undervalued intrinsic discount59
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative